Search

Now showing items 1-5 of 5

Embolization of patent foramen ovale closure devices: incidence, role of imaging in identification, potential causes, and management.

Aksoy, O; Goel, SS; Kapadia, SR; Krasuski, Richard Andrew; Tuzcu, EM (Tex Heart Inst J, 2013)

Transcatheter patent foramen ovale (PFO) closure is an alternative to antiplatelet or anticoagulative therapy in patients with cryptogenic stroke, and it is associated with a small incidence of periprocedural sequelae. Because ...

Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.

Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, Bernard John; Holmes, DaJuanicia; Hylek, EM; ... (15 authors) (J Am Heart Assoc, 2013-11-25)

BACKGROUND: Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial fibrillation. Adoption patterns of this new agent in community practice are unknown. METHODS AND RESULTS: We studied patterns ...

Racial differences in the prevalence and outcomes of atrial fibrillation among patients hospitalized with heart failure.

Fonarow, GC; Get With the Guidelines Steering Committee and Hospitals; Hernandez, Adrian Felipe; Liang, L; Peterson, Eric David; Piccini, Jonathan Paul Sr; Thomas, Kevin Lindsey; ... (8 authors) (J Am Heart Assoc, 2013-09-26)

BACKGROUND: The intersection of heart failure (HF) and atrial fibrillation (AF) is common, but the burden of AF among black patients with HF is poorly characterized. We sought to determine the prevalence of AF, characteristics, ...

PINOT NOIR: pulmonic insufficiency improvement with nitric oxide inhalational response.

Arruda, J; Bolen, M; Boonyasirinant, T; Devendra, Ganesh P; Flamm, Scott D; Hart, Stephen A; Kalahasti, V; ... (11 authors) (J Cardiovasc Magn Reson, 2013-09-04)

BACKGROUND: Tetralogy of Fallot (TOF) repair and pulmonary valvotomy for pulmonary stenosis (PS) lead to progressive pulmonary insufficiency (PI), right ventricular enlargement and dysfunction. This study assessed whether ...

Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III.

Austin, S; Bali, Deeksha Sarihyan; Chen, Y-T; Fredrickson, Keri B; Kishnani, Priya Sunil; Kraus, William Erle; Sun, Baodong; ... (9 authors) (Mol Genet Metab, 2013-02)

We investigated the feasibility of using recombinant human acid-α glucosidase (rhGAA, Alglucosidase alfa), an FDA approved therapy for Pompe disease, as a treatment approach for glycogen storage disease type III (GSD III). ...